Overview

Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction

Status:
Completed
Trial end date:
2017-07-19
Target enrollment:
Participant gender:
Summary
Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Hydroxyitraconazole
Itraconazole
Rifampin